Clinical study of Montelukast sodium combined with budesonide in the treatment of 89 children with asthma
YAN Xianpeng
YAN Xiaohua
REN Linjuan
GAO Na
WANG Jieying
Abstract：Objective To explore the clinical efficacy of Montelukast sodium combined with budesonide in the treatment of 89 children with asthma,and to provide data for treatment of asthma in children.Methods This study enrolled 89 children with asthma treated between December 2015 and December 2016 in Shanxi Provinciar Reople's Hospital.The clinical data was retrospectively analyzed to compare the curative effect.48 of these cases who received Montelukast sodium combined with budesonide treatment were assigned to the observation group,while 41 of these children who received budesonide treatment were selected as the control group.Clinical efficacy was compared after three consecutive months of treatment,so were cough and wheeze extinction time of the two groups.Preoperative and postoperative levels of serum procalcitonin (PCT) and C-reactive protein (CRP) of the two groups were detected through enzyme-linked immunosorbent assay (ELISA),and the immunoglobulin E (IgE) level was determined.At the same time,pulmonary function indexes before and after treatment were compared,and the recurrence and adverse reactions were recorded within the follow-up period.Results The total effective rate of the observation group was 95.83%,which was significantly higher than that of the control group (85.37%),so the difference was of statistical significance (P＜0.05).The cough and wheeze extinction time of the observation group was significantly shorter than that of the control group (P＜0.05).PCT,CRP,and IgE levels of the two groups were significantly decreased after treatment,especially in the observation group,and the difference was statistically significant (P＜0.05).FVC,FEV1 and FEV1/FVC levels of the two group were significantly increased after treatment,especially in the observation group,and the difference between the two groups was of statistical significance (P＜0.05).The incidence of adverse reactions of the two groups was not significantly different (P＞0.05),but the recurrence rate of the observation group was significantly lower than that of the control group (P＜0.05).Conclusion Compared with budesonide treatment alone,the combined treatment with Montelukast sodium can significantly improve clinical efficacy of asthma in children,reduce recurrence and inflammatory responses,and enhance lung function as well.
Keywords：Montelukast sodiumBudesonideasthma in children
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 192-195 )